The effect of empagliflozin on monocyte high-density lipoprotein ratio in patients with type 2 diabetes mellitus

Authors : Murat DOĞAN

Pages : 255-259

Doi:10.38053/acmj.1098603

View : 25 | Download : 13

Publication Date : 2022-07-26

Article Type : Research Paper

Abstract :Aim: We aimed to investigate the effect of empagliflozin, which is started in patients with type 2 diabetes mellitus (T2DM), on neutrophil leumphocyte ratio (NLR) and monocyte high-density lipoprotein ratio (MHR), which are used as inflammation, glycemic control and oxidative markers. Material and Method: The file systems of T2DM patients who used empagliflozin for at least 12 weeks were retrospectively analyzed. Demographic data of the patients were recorded. biochemical and hemogram parameters were compared before and after empagliflozin. Results: 194 patients were included in the study. Plasma fasting glucose (p<0.001), hemoglobin A1c (HbA1c)(p<0.001), low-density lipoprotein cholesterol (LDL-C) (p=0.041), NLR(p=0.002) and MHR(p=0.042) values of T2DM patients after empagliflozin treatment were statistically significantly decreased compared to pre-treatment with empagliflozin. HDL-C value(p=0.003), on the other hand, increased significantly after empagliflozin Conclusion: NLR and MHR are inexpensive and practical markers of inflammation. This result shows us that NLR and MHR should be used as inflammation markers in patients using empagliflozin.
Keywords : Empagliflozin, MHR, NLR